Targeted missile drug aims to blast teen bone cancer
NCT ID NCT04616560
Summary
This study is testing a drug called trastuzumab deruxtecan (DS-8201a) for young people (ages 12-39) whose HER2-positive osteosarcoma, a type of bone cancer, has come back. The drug is designed to act like a targeted missile, attaching to cancer cells and delivering chemotherapy directly to them. The main goal is to see how many patients are free from their cancer getting worse after 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030, United States
-
C S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, 30329, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Alabama
Birmingham, Alabama, 35233, United States
-
Children's Hospital of Orange County
Orange, California, 92868, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224, United States
-
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, 64108, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Lurie Children's Hospital-Chicago
Chicago, Illinois, 60611, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
UCSF Medical Center-Mission Bay
San Francisco, California, 94158, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.